Loading clinical trials...
Loading clinical trials...
A Multicenter, Phase 1b, Double-blind, Placebo-controlled Study to Evaluate the Safety and Tolerability, and the Efficacy of Si-544 in Adults With Psoriasis Vulgaris or Psoriatic Arthritis
Conditions
Interventions
si-544
Placebo
Locations
4
Germany
selectION Clinical Trial Site
Bad Bentheim, Germany
selectION Clinical Trial Site
Berlin, Germany
selectION Clinical Trial Site
Blankenfelde-Mahlow, Germany
selectION Clinical Trial Site
Hamburg, Germany
Start Date
January 22, 2024
Primary Completion Date
June 23, 2025
Completion Date
June 23, 2025
Last Updated
July 3, 2025
NCT07295509
NCT07286058
NCT06100744
NCT04402086
NCT06888193
NCT07315061
Lead Sponsor
selectION Therapeutics GmbH
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions